Cargando…
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
Darolutamide (NUBEQA(®)) is an oral androgen receptor inhibitor (ARi) that is approved for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) and docetaxel. In a pivotal trial, darolutamide plus ADT and docetaxel was superior...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517889/ https://www.ncbi.nlm.nih.gov/pubmed/37542594 http://dx.doi.org/10.1007/s11523-023-00984-4 |